FORT WORTH, Texas, Oct. 6 /PRNewswire/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary Wound Care Innovations, LLC has added the company's first pharmacy client to its rapidly growing list of customers. Lewis Hall, Inc. of Fort Worth, TX is an independent pharmacy group that has several locations and 30 years experience in wound care, long term care and specialty compounded products for dermatologic use. Lewis Hall, company president, was quoted as saying, "We are genuinely excited about having Cellerate RX® as part of our product line. It has had such tremendous outcomes that we believe our customers will find it to be one of the best wound healing products in the market."
This order punctuates a string of recent successes for WCI in the 3rd Quarter resulting in the company having the best sales order quarter in its history, with one order for over $300,000 of products that will be shipped during the 4th quarter of 2010. WCI continues to surge ahead in the execution of its growth strategy highlighted by its expansion in the South African and Central American markets as well as in the government sector through its addition of Veterans Health Administration facilities in Texas and Florida as announced last month.
Ronald D. Mathis, Senior Vice President of Marketing and Sales said, "We understand that sales growth rarely happens at the pace that everyone would prefer. However, what we are seeing here is the focused execution of a highly developed plan that has the opportunity to yield phenomenal results for both Wound Management Technologies and its shareholders."
WNDM is filing a Form 8k today about recent company progress along with a presentation being made on October 7, 2010 to the investment community.
For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board:WNDM.ob - News) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on Cellerate RX®, please visit the WCI web site at http://www.celleraterx.com/ .
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com, and http://www.secureehealth.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications (817)820-7077
SOURCE Wound Management Technologies, Inc.